SAMPLE REPORT
1280 CardioMetabolic-META® (Blood)
Metabolic Syndrome is a condition characterized by a combination of factors such as visceral fat accumulation, abnormal glucose metabolism, hypertension, lipoprotein quality and metabolic abnormalities, and genetic predispositions. Underlying this syndrome may be clinically silent but significant issues such as adipokine imbalance, insulin resistance, endothelial dysfunction, and vascular inflammation. The more of these factors that are present simultaneously, the higher the risk of developing chronic diseases. Clinically, metabolic syndrome is used as a risk assessment tool for atherosclerosis, cardiovascular disease, and type 2 diabetes.
This assessment provides a more in-depth evaluation of the early indicators of metabolic syndrome through the following key areas : Visceral fat and glucose metabolism, Lipid and cholesterol quality and metabolism, HDL antioxidant capacity and Vascular inflammation and atherosclerosis.
Relying solely on cholesterol levels, elevated LDL-C, or the idea that “the higher HDL-C, the better” is now considered an outdated perspective in modern medicine.
SAMPLE REPORT
Testing Content
CardioMetabolic Disease
Cardiometabolic Diseases refer to a range of metabolic dysfunctions, including elevated blood pressure, abnormal blood lipid levels, high blood sugar, and increased waist circumference. These are warning signs of potential health risks, and individuals with these conditions are at significantly higher risk of developing cardiovascular diseases.
The primary contributing factors include obesity, physical inactivity, poor dietary habits, and insulin resistance—which is one of the most common physiological issues in these patients. Normally, glucose in the blood requires insulin to enter the cells. However, with insulin resistance, the cells become less responsive to insulin, making it harder for glucose to be absorbed. As a result, insulin is less effective in lowering blood sugar levels, leading to elevated glucose levels and metabolic disruption.
| Possible Complications of Cardiometabolic Diseases | |
|---|---|
| Gout, Hyperuricemia, Diabetes | Hypertension(Arteriosclerosis), Vascular endothelium damage |
| Obesity(Visceral fat accumulation) | Atherosclerosis(Stroke), Plaque rupture |
Functional medicine testing and assessment
- Visceral Fat and Blood Sugar Regulation
The secretion and resistance of adipokines (fat-derived hormones), along with insulin resistance, affect the cells' sensitivity to insulin. This impairs glucose uptake into cells for energy metabolism, leading the body to compensate by secreting more insulin—resulting in a condition of hyperinsulinemia. It is essential to focus on reducing visceral fat and improving insulin sensitivity and abnormal glucose metabolism. - Lipoprotein Quality, Quantity, and Metabolic Balance
Lipid metabolism disorders are a key indicator of cardiovascular disease risk. In addition to lowering triglycerides, it is important to regulate lipoprotein balance and enhance the antioxidant capacity of high-density lipoprotein (HDL) to maintain normal metabolic function. - Vasculitis and Atherosclerosis
Inflammation often occurs silently without obvious symptoms, yet it is ongoing and persistent. Chronic inflammation can lead to plaque rupture, arterial hardening, and cardiovascular diseases, as well as obesity and metabolic syndrome, contributing to insulin resistance and diabetes. Maintaining a balance between inflammatory markers and antioxidants in the body is crucial. - Endothelial Function
The endothelium regulates vascular contraction and relaxation, largely through nitric oxide (NO), an endogenous vasodilator. A deficiency in NO can result in endothelial dysfunction and vascular stiffness. Endothelial dysfunction is an early marker of atherosclerosis, and the vessel walls are central to the development of cardiovascular diseases.
The important information provided by CardioMetabolic-META® is as follows
- Cardiometabolic Disease refers to the clustering of multiple risk factors such as cardiovascular disease and diabetes. Increased visceral fat and insulin resistance are major contributing factors to cardiometabolic disorders. There are two primary strategies for managing these conditions: Lifestyle modification — including dietary changes, weight control, and increased physical activity.Treatment of individual cardiovascular risk factors.
- Research indicates that visceral fat is more metabolically active than subcutaneous fat and has a stronger association with cardiovascular disease. Visceral fat actively releases free fatty acids, promoting insulin resistance and triggering metabolic abnormalities, which in turn lead to the accumulation of risk factors such as high blood sugar, high blood pressure, and high cholesterol. Blood sugar regulation is one of the key factors in this process.
- When cells or tissues become resistant to insulin, insulin sensitivity decreases. As a result, insulin cannot function properly in peripheral tissues, and glucose remains in the bloodstream rather than entering cells. The greater the degree of insulin resistance, the more severe the symptoms of metabolic syndrome become.
- Chronic inflammation exposes tissues and cells to long-term stimulation by inflammatory cytokines, which gradually causes tissue damage throughout the body. Supplementing with anti-inflammatory substances can help reduce the production of these inflammatory markers—such as by lowering oxidized LDL (oxLDL) formation and increasing glutathione levels.
- Reducing excessive free radicals and maintaining a healthy balance between oxidative stress and antioxidant defenses is essential. Moderate supplementation with antioxidants such as vitamin C and vitamin E can be helpful. Trace minerals also play a role in enhancing antioxidant capacity—copper, zinc, manganese, and organic selenium can be obtained from whole grains, shellfish, legumes, brewer’s yeast, vegetables, and fruits.
